Author:
Rabahi Marcelo Fouad,Junqueira-Kipnis Ana Paula,dos Reis Michelle Cristina Guerreiro,Oelemann Walter,Conde Marcus Barreto
Abstract
Abstract
Background
Tuberculosis (TB) remains a major world health problem. Around 2 billions of people are infected by Mycobacterium tuberculosis, the causal agent of this disease. This fact accounts for a third of the total world population and it is expected that 9 million people will become infected each year. Only approximately 10% of the infected people will develop disease. However, health care workers (HCW) are continually exposed to the bacilli at endemic sites presenting increased chance of becoming sick. The objective of this work was to identify LTBI (latent tuberculosis infection) among all asymptomatic HCW of a Brazilian Central Hospital, in a three year follow up, and evaluate the humoral response among HCW with previous and recent LTBI to recombinant HspX and GlcB from M. tuberculosis.
Methods
Four hundred and thirty seven HCW were screened and classified into three different groups according to tuberculin skin test (TST) status: uninfected, previous LTBI and recent LTBI. ELISA test were performed to determine the humoral immune response to HspX and GlcB.
Results
The levels of IgG and IgM against the HspX and GlcB antigens were the same among HCW with recent and previous LTBI, as well as among non infected HCW. However, the IgM levels to HspX was significantly higher among HCW with recent LTBI (OD = 1.52 ± 0.40) than among the uninfected (OD = 1.09 ± 0.50) or subjects with previous LTBI (OD = 0.96 ± 0.51) (p < 0.001).
Conclusion
IgG and IgM humoral responses to GlcB antigens were similar amongst all studied groups; nevertheless IgM levels against HspX were higher among the recent LTBI/HCW.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. World Health Organization: Global tuberculosis control: surveillance, planning, financing. WHO Report. 2006, Geneva, Switzerland, Accessed December 2006, [http://www.who.int/tb/publications/global_report/2006/summary/en/index.html]
2. The global plan to stop TB, 2006–2015 Geneva: Stop TB Partnership 2006:1–172. Accessed December 2006, [http://www.stoptb.org/globalplan/assets/documents/SSP_DIAGWG.pdf]
3. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970, 26: 28-106.
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000, 161 (4 Pt 2): S221-S247.
5. Jasmer RM, Nahid P, Hopewell PC: Latent tuberculosis infection. N Engl J Med. 2002, 347: 1860-1866. 10.1056/NEJMcp021045.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献